Jazz Pharmaceuticals Announces Initiation of Phase 3 Trial Evaluating Epidiolex®/Epidyolex® (cannabidiol) for Patients with Epilepsy with Myoclonic-Atonic SeizuresPRNewsWire • 08/18/22
Wall Street Analysts Predict a 25% Upside in Jazz (JAZZ): Here's What You Should KnowZacks Investment Research • 08/16/22
Jazz Pharmaceuticals (JAZZ) Q2 Earnings and Revenues Beat EstimatesZacks Investment Research • 08/03/22
Jazz Pharmaceuticals plc (JAZZ) CEO Bruce Cozadd on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/03/22
Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial GuidancePRNewsWire • 08/03/22
Does Jazz (JAZZ) Have the Potential to Rally 25% as Wall Street Analysts Expect?Zacks Investment Research • 07/28/22
Jazz Pharmaceuticals to Report 2022 Second Quarter Financial Results on August 3, 2022PRNewsWire • 07/20/22
Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-TermZacks Investment Research • 07/13/22
How Much Upside is Left in Jazz (JAZZ)? Wall Street Analysts Think 28%Zacks Investment Research • 07/12/22
Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis SpasticityPRNewsWire • 06/28/22